Progress in Neuro-Psychopharmacology and Biological Psychiatry

Aims & Scope

Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry.

Issues of the journal are regularly devoted wholly in or in part to a topical subject.

Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	3.9
2024	5.30

SJR (SCImago Journal Rank)

Year	Value
2024	1.768

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	157

Journal Rank

Year	Value
2024	1785

Journal Citation Indicator

Year	Value
2024	3686

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Neuroscience and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Limbic system mechanisms of stress regulation: Hypothalamo-pituitary-adrenocortical axis

  Citation: 1062

  Authors: James P., Michelle M., Nancy K., Helmer

• A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness

  Citation: 959

  Authors: Michael, Piotr, Yong Seun, Michael

• Cytokines and major depression

  Citation: 929

  Authors: Olga J.G., Marieke C., Michael

• Evidence for an immune response in major depression: A review and hypothesis

  Citation: 774

  Authors: Michael

• Serotonin receptors : their key role in drugs to treat schizophrenia

  Citation: 627

  Authors: Herbert Y, Zhu, Yasuhiro, Junji

• The new ‘5-HT’ hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression

  Citation: 566

  Authors: M., B.E., A.M., M., R.

• Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex

  Citation: 543

  Authors: Shuichi, Tadahiro, Midori, Misty C., Chisato, Hiroshi

• Younger people are more vulnerable to stress, anxiety and depression during COVID-19 pandemic: A global cross-sectional survey

  Citation: 533

  Authors: Prerna, Moira, Hailey, Melinda L.

• Drug craving and addiction: integrating psychological and neuropsychopharmacological approaches

  Citation: 523

  Authors: Ingmar H.A.

• Monoamine neurocircuitry in depression and strategies for new treatments

  Citation: 518

  Authors: Michel, Pierre

---